Organon (OGN) shares declined 22% in recent Thursday trading after the company reported Q1 adjusted earnings of $1.02 per diluted share, down from $1.22 a year earlier.
Analysts polled by FactSet expected $0.89.
Revenue for the quarter ended March 31 was $1.51 billion, down from $1.62 billion a year earlier.
Four analysts surveyed by FactSet expected $1.51 billion.
The company said it maintained its 2025 revenue outlook of $6.13 billion to $6.33 billion. Analysts surveyed by FactSet expect $6.29 billion.
Price: 9.40, Change: -3.54, Percent Change: -27.34
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.